Orforglipron (Foundayo)

Also known as: Foundayo

Profile at a glance

AttributeValue
SponsorEli Lilly
MechanismGLP-1 receptor agonist (non-peptide small molecule)
AdministrationOnce-daily oral pill — no food or water restrictions
Peak weight loss~12.4% at 72 weeks (ATTAIN-1)
StatusFDA-approved April 2026 — first non-peptide oral GLP-1 agonist

Deep dive

What Is Foundayo (Orforglipron)? Lilly's FDA-Approved Oral GLP-1 Weight Loss Pill

Eli Lilly's FDA-approved oral GLP-1 pill — 12.4% weight loss, no injections, no fasting. Starting at $149/month.

See all drug profiles in the drug profiles hub or compare drugs head-to-head in the comparisons hub.